NPY and cardiovascular disorders

Plasma levels of NPY are elevated in several cardiovascular diseases in which vaso- 

To conclude, the presendy available Y1 antagonists have at last made it possible to establish that endogenous NPY can act as a sympathetic vasoconstrictor. The next task is to study the relevance of NPY in cardiovascular pathophysiology in various animal models. With the development of more potent and selective NPY antagonists, these studies should ultimately be extended to include man. 

Ahlborg, G., Weitzberg, E., Sollevi, A. Lundberg, J.M. (1992) Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man. Acta 

Ghilardi, J.R., Vigna, S.R., Mannon, PJ., Taylor, I.L., McVey, D.C. et al. (1993) Neuropeptide Y/peptide YY receptor binding sites in the heart Localization and pharmacological characterization. Neuroscience 53, 889-898. 

Andersson, F.L., Port, J.D., Reid, B.B., Larrabee, R, Hanson, G. Bristow, M.R. (1992) Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with fl-adrenergic receptor downregulation. Circulation 85, 45-53. 

---